Table 1.
Characteristics of included studies
| NO. | Author | Empagliflozin group | Control group | Jada scores |
||||||||||
| No | Age (years) | Female (n) |
Body mass index (kg/m2) |
Statin use (n) |
Methods | No | Age (years) | Female (n) |
Body mass index (kg/m2) |
Statin use (n) |
Methods | |||
| 1 | Chehrehgosha 2021 | 35 | 50.5±8.4 | 20 | 30.9±3.3 | 34 | empagliflozin 10 mg daily for 24 weeks |
37 | 51.8±7.8 | 23 | 30.2±4.4 | 35 | placebo | 5 |
| 2 | Taheri 2020 | 43 | 43.8±9.7 | 15 | 30.5±2.3 | 5 | empagliflozin (10 mg/day) for 24 weeks |
47 | 44.1±9.3 | 25 | 30.7±3.5 | 6 | placebo | 5 |
| 3 | Kuchay 2018 | 25 | 50.7±12.8 | 9 | 30.0±3.8 | - | empagliflozin (10 mg/day) for 20 weeks |
25 | 49.1±10.3 | 8 | 29.4±3.1 | - | placebo | 4 |